Forensic Toxicology Laboratory, Institute of Environmental Science and Research Limited (ESR), Porirua, New Zealand.
Faculty of Science and School of Chemistry, The University of Sydney, NSW, Australia.
Drug Test Anal. 2020 Feb;12(2):195-214. doi: 10.1002/dta.2697. Epub 2019 Nov 28.
We describe the validation of a method for the simultaneous analysis of 29 synthetic cannabinoids (SCs) and metabolites, 4 amphetamines, and 2 cannabinoids in human whole blood. This method enables one analysis to cover what previously required multiple analyses for these classic and novel drugs-of-abuse with diverse physicochemical properties. The scope of targeted analytes was based on the most prevalent drugs-of-abuse and SCs encountered at the New Zealand border in 2017 and included parent compounds and metabolites belonging to the indole and indazole carboxamide, quinolinyl indole carboxylate, and naphthoylindole classifications. Samples were prepared by supported-liquid-extraction (SLE) followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis with positive electrospray ionization (ESI). The method was validated with respect to selectivity, matrix effects, process efficiency, sensitivity, repeatability, extract stability, and carryover for qualitative confirmation. Linearity as well as accuracy and precision data at target decision concentrations were also evaluated. The limits of detection and confirmation ranged from 0.1 to 6.0 ng/mL and 1.0 to 6.0 ng/mL, respectively. The described method was successfully applied to the analysis of 564 ante- and post-mortem blood samples in 2018. There were 132 cases (23%) with positive findings of at least one SC, with the five most commonly detected SCs being AMB-FUBINACA and/or acid (61%), 5F-ADB and/or acid (40%), ADB-FUBINACA (11%), 5F-MDMB-PICA acid (6%), and MDMB-FUBINACA acid (6%). The results also demonstrate the predominant presence of metabolites at higher levels than the unchanged parent SCs in blood, highlighting the need to maintain forensic screening methods capable of the simultaneous detection of both parent compounds and metabolites.
我们描述了一种同时分析 29 种合成大麻素(SCs)和代谢物、4 种苯丙胺和 2 种大麻素在人全血中的方法的验证。这种方法使得一次分析可以涵盖以前需要对具有不同物理化学性质的这些经典和新型药物滥用物进行多次分析的内容。靶向分析物的范围基于 2017 年在新西兰边境遇到的最常见的药物滥用物和 SC,包括属于吲哚和吲哚甲酰胺、喹啉基吲哚羧酸酯和萘酰基吲哚分类的母体化合物和代谢物。样品通过固相萃取(SLE)制备,然后进行液相色谱-串联质谱(LC-MS/MS)分析,采用正电喷雾电离(ESI)。该方法在选择性、基质效应、处理效率、灵敏度、重复性、提取物稳定性和定性确证的交叉污染方面进行了验证。还评估了目标决策浓度的线性以及准确度和精密度数据。检测限和确认限分别为 0.1 至 6.0ng/mL 和 1.0 至 6.0ng/mL。该方法已成功应用于 2018 年 564 例生前和死后血液样本的分析。有 132 例(23%)至少有一种 SC 的检测结果为阳性,其中最常检测到的五种 SC 为 AMB-FUBINACA 和/或酸(61%)、5F-ADB 和/或酸(40%)、ADB-FUBINACA(11%)、5F-MDMB-PICA 酸(6%)和 MDMB-FUBINACA 酸(6%)。结果还表明,代谢物的存在水平明显高于血液中的未改变母体 SC,这突出表明需要维持能够同时检测母体化合物和代谢物的法医筛选方法。